CClinicalTrials.gg
Status unknownNCT02361073Updated Feb 11, 2015

The Role of Emotional Stress in Patients With Stress-induced Cardiomyopathy

An observational study in Takotsubo Cardiomyopathy, sponsored by University of Magdeburg. Status unknown at 1 site in Germany. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-11.

Sponsored by University of Magdeburg · Observational

The sponsor has not verified this record recently (last verified Feb 2015), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The event-related potentials may be different in patients with Takotsubo cardiomyopathy than in patients without Takotsubo.

Read the detailed description

In patients with Takotsubo diagnosed by coronary angiography, the event-related potentials are investigated and compared with a control group, which consists of subjects without Takotsubo.

02

Conditions studied

  • Takotsubo Cardiomyopathy

Keywords

  • Stress-induced cardiomyopathy
  • ERP
03

In context

Cardiomyopathies

1,176 studies on the registry are indexed under Cardiomyopathies; 287 are open to participants now.

This study's planned enrollment of 30 is below the median of 153 across 515 observational studies indexed under Cardiomyopathies.

Browse Cardiomyopathies studies →

Lead sponsor

University of Magdeburg is the lead sponsor of 33 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with Takotsubo Cardiomyopathy compared with healthy subjects and patients with ACS.

Inclusion criteria

  • Age >18 years
  • Written informed consent
  • Takotsubo cardiomyopathy for group 1. ACS for group 3.

Exclusion criteria

Exclusion Criteria:

  • Psychiatric diseases
  • Impaired versus, non compliant patients, heart disease for group 2.
  • Takotsubo-like syndrome.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Takotsubo
  • Healthy
  • ACS
06

What researchers measure

Primary outcomes

  1. Event-related potentials

    Time frame: up to 1 year

07

Study locations

1 of 1 sites recruiting
  • University Hospital Magdeburg
    Magdeburg, 39112, Germany
    • Samir M Said, MD · Principal investigator
    • Katja Mueller · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02361073
Lead sponsor
University of Magdeburg
Responsible party
Dr. Samir Said (MD, University of Magdeburg) — Principal investigator
First posted
Feb 11, 2015
Start date
Jun 2011
Primary completion
Aug 2015 (estimated)
Completion
Aug 2015 (estimated)
Last update
Feb 11, 2015

Study contacts

Samir M Said, MD
Contact
samir.said@med.ovgu.de
+49-3916715206
Katja Mueller
Contact
katja.mueller@med.ovgu.de
+49-1604429214

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion